Short-term Naltrexone Use Associated with Delayed-onset Fever and Hepatotoxicity: A Case Report

10.4103/TPSY.TPSY_33_22

Chao-Chun Hsu；Yu-Hui Ku；Hong-Ming Chen

台灣精神醫學

36卷4期（2022 / 12 / 01）

188 - 189

英文

1. (2012).Opioids: LiverTox: Clinical and Research Information on Drug-induced Liver Injury. Bethesda, Maryland, USA: National Institute of Diabetes and Digestive and Kidney Diseases, 2012..
2. Anton, RF,O’Malley, SS,Ciraulo, DA(2006).Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: a randomized controlled trial.JAMA,295,2003-2017.
3. Bolton, M,Hodkinson, A,Boda, S(2019).Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.BMC Med,17,10.
4. Handler, CM,Price, RW,Geller, EB(1998).Effect of mu-selective opioid antagonists on MIP-1 beta and IL-1 beta-induced fever.Ann N Y Acad Sci,856,270-273.
5. Kim, SW,Grant, JE,Yoon, G(2006).Safety of high-dose naltrexone treatment: Hepatic transaminase profiles among outpatients.Clin Neuropharmacol,29,77-79.
6. Mitchell, JE,Morley, JE,Levine, AS(1987).High-dose naltrexone therapy and dietary counseling for obesity.Biol Psychiatry,22,35-42.
7. Pfohl, DN,Allen, JI,Atkinson, RL(1986).Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.NIDA Res Monogr,67,66-72.
8. Reus, VI,Fochtmann, LJ,Bukstein, O(2018).The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder.Am J Psychiatry,175,86-90.
9. Shen, WW(2018).Anticraving therapy for alcohol use disorder: a clinical review.Neuropsychophamacol Rep,38,105-116.
10. Yen, MH,Ko, HC,Tang, FI(2006).Study of hepatotoxicity of naltrexone in the treatment of alcoholism.Alcohol,38,117-120.